BDCRB
BDCRB is a selective Human cytomegalovirus (HCMV) inhibitor through blocking the maturational cleavage of high-molecular-weight DNA. BDCRB shows a mean IC50 of 0.03 μM for viral yield at 72 h postinfection[1].
Product Specifications
CAS Number
142356-43-2
Product Name Alternative
2-Bromo-5,6-dichloro-1-β-D-ribofuranosyl benzimidazole
UNSPSC
12352005
Target
CMV
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/bdcrb.html
Solubility
10 mM in DMSO
Smiles
O[C@H]1[C@H](N2C3=CC(Cl)=C(Cl)C=C3N=C2Br)O[C@H](CO)[C@H]1O
Molecular Formula
C12H11BrCl2N2O4
Molecular Weight
398.04
References & Citations
[1]Biron KK, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother. 2002 Aug;46 (8) :2365-72.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
